Navigation Links
Therapure Biopharma Inc. Announces Manufacturing Agreement with Biomedical Frontiers Incorporated -- Contract will Support Phase II Trials for Thalassemia Treatment
Date:11/28/2008

Thomas Wellner, President and CEO of Therapure Biopharma Inc. today announced that the Company has signed a biomanufacturing services agreement with Minnesota-based Biomedical Frontiers Incorporated for the production of an iron chelating agent used in the treatment of thalassemia, an inherited blood disorder.

Toronto, ON (PRWEB) November 28, 2008 - Thomas Wellner, President and CEO of Therapure Biopharma Inc. today announced that the Company has signed a biomanufacturing services agreement with Minnesota-based Biomedical Frontiers Incorporated for the production of an iron chelating agent used in the treatment of thalassemia, an inherited blood disorder.

Therapure Biopharma will apply experience gained previously in the production of Biomedical Frontiers' deferoxamine conjugates, which are injectable iron-binding drugs used to neutralize iron build-up in the blood of patients with an iron overload disorder. Biomedical Frontiers believes that their product offers advantages over existing treatments for thalassemia that will result in improved patient compliance and therefore better clinical outcomes.

In addition to manufacturing clinical trial supplies, Therapure Biopharma will provide debt financing that will partially support Biomedical Frontiers' Phase II clinical program for the product. The contract also gives Therapure Biopharma long-term commercial manufacturing rights when the product is approved by regulators.

"Production of this compound for Biomedical Frontiers is a great example of the flexibility of our modern biomanufacturing facility," said Thomas Wellner. "We are able to produce the necessary supplies of their compound quickly to support the continuing clinical development of this important new product."

"We previously contracted with Therapure Biopharma in the manufacture of drug material to support our successful development program", said Bo Erik Hedlund, President and Chief Executive Officer of Biomedical Frontiers. "Because of this earlier experience, we are very confident in Therapure Biopharma's ability to produce a high-quality product within the timelines we need to start our Phase II trials. Securing both a manufacturer and a financial contribution from Therapure Biopharma will make it much easier for us to acquire the additional funding we need to complete these studies and bring a more effective and user-friendly treatment for thalassemia and other iron overload disorders to markets."

About Therapure Biopharma:

Therapure Biopharma Inc. is an integrated biopharmaceutical company that develops, manufactures, purifies, and packages therapeutic proteins. Therapure Biopharma acquired its Canadian-built and conceived facility from Hemosol Corporation, a specialist in therapies derived from hemoglobin, a blood protein. Therapure Biopharma applies scientific, manufacturing, and downstream purification expertise with an intimate understanding of advanced biology, complex proteins, and regulatory processes to develop effective and innovative solutions to advance products from discovery to market.

For more information, please visit: www.therapurebio.com

About Biomedical Frontiers, Incorporated:

Biomedical Frontiers Incorporated ("BMF or the Company") is a privately held biopharmaceutical company with a focus on developing innovative iron-binding drugs for the treatment of iron overload disorders and acute iron poisoning. BMF's proprietary technical platform involves chemical coupling of drugs to biocompatible polymers. The Company is currently preparing for a Phase II clinical trial for its proprietary lead iron-binding drug, starch-conjugated deferoxamine, in patients with transfusion dependent thalassemia.

For more information, please contact: Bo Hedlund, Ph.D. 612-281-4033

###

Read the full story at http://www.prweb.com/releases/2008/11/prweb1675504.htm


'/>"/>
Source: PRWeb
Copyright©2008 Vocus, Inc.
All rights reserved

Related biology technology :

1. Therapure Biopharma Inc. opens for business with first client contracts
2. Therapure Biopharma Inc. announces collaboration with Induce Biologics Inc.
3. Therapure Biopharma Inc. announces collaboration with BioVectra Inc.
4. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
5. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
6. PDL BioPharma Announces Internal CEO Investigation Found No Credible Evidence of Improper Personal Conduct or Breach of Fiduciary Duty
7. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
8. PDL BioPharma Announces Significant Strategic and Portfolio Changes to Focus on Antibody Discovery and Development
9. XTL Biopharmaceuticals Announces Presentation of Novel Pre-Clinical Inhibitors of Hepatitis C at an Upcoming International Scientific Conference
10. XTL Biopharmaceuticals Initiates Phase IIb Clinical Trial of Bicifadine for the Treatment of Diabetic Neuropathic Pain
11. Nabi Biopharmaceuticals Announces Sale of Nabi Biologics to Biotest AG
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/4/2016)... BEIJING , Feb. 4, 2016 Sinovac ... ), a leading provider of biopharmaceutical products in ... committee of its board of directors received on February ... 3, 2016, from a consortium comprised of PKU V-Ming ... Sinobioway Biomedicine Co., Ltd., CICC Qianhai Development ( ...
(Date:2/4/2016)... ... February 04, 2016 , ... Many of the engineers at ... years. What sets them apart from other cuvette manufacturers is their supercharged customer ... website. On top of this steady flow of inside information, they have recently ...
(Date:2/3/2016)... -- With the growing need for better therapeutics, and ... such as monoclonal antibodies, recombinant protein therapeutics and ... are in high demand. Conventionally expression systems were ... of these therapeutics. However, due to issues with ... approaches and novel expression systems are currently being ...
(Date:2/3/2016)... , Feb. 3, 2016 New ... more than $1 million for researchers in ... on health-related research that demonstrates exciting potential.   ... of funding for the New Jersey Health Foundation Research ... members at these educational institutions— Princeton University, Rutgers ...
Breaking Biology Technology:
(Date:1/25/2016)... SEATTLE , Jan. 25, 2016  Glencoe Software, ... biotech, pharma and publication industries, will provide the data ... Phenotypic Screening Centre (NPSC). ... Phenotypic analysis ... even whole organisms, allowing comparisons between states such as ...
(Date:1/21/2016)... 21, 2016 --> ... market research report "Emotion Detection and Recognition Market by Technology ... (Facial Expression, Voice Recognition and Others), Services, Application ... to 2020", published by MarketsandMarkets, the global Emotion ... USD 22.65 Billion by 2020, at a CAGR ...
(Date:1/20/2016)... SAN JOSE, Calif. , Jan. 20, 2016 ... leading developer of human interface solutions, today announced ... touch controller solution for wearables and small screen ... appliances such as printers. Supporting round and rectangular ... the S1423 offers excellent performance with moisture on ...
Breaking Biology News(10 mins):